BidaskClub Lowers Sarepta Therapeutics (NASDAQ:SRPT) to Hold

Share on StockTwits

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports.

Other research analysts also recently issued research reports about the company. Needham & Company LLC lowered their target price on Sarepta Therapeutics from $196.00 to $170.00 and set a “buy” rating on the stock in a report on Wednesday, August 21st. Royal Bank of Canada set a $204.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright set a $160.00 price target on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Friday, September 13th. Morgan Stanley reduced their price target on Sarepta Therapeutics from $220.00 to $160.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Finally, Robert W. Baird reduced their price target on Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating for the company in a research report on Tuesday, August 20th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. Sarepta Therapeutics has an average rating of “Buy” and an average price target of $187.06.

SRPT stock opened at $101.45 on Tuesday. Sarepta Therapeutics has a fifty-two week low of $72.05 and a fifty-two week high of $158.80. The business’s 50-day moving average is $98.96 and its two-hundred day moving average is $111.06. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.54 and a current ratio of 6.31. The company has a market cap of $8.16 billion, a price-to-earnings ratio of -18.58 and a beta of 2.29.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.35). Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 55.44%. The firm had revenue of $99.04 million during the quarter, compared to the consensus estimate of $98.49 million. During the same period in the prior year, the company posted ($1.15) EPS. The firm’s revenue was up 26.2% compared to the same quarter last year. Equities analysts predict that Sarepta Therapeutics will post -6.02 earnings per share for the current year.

In other Sarepta Therapeutics news, Director Richard Barry bought 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was purchased at an average price of $87.49 per share, for a total transaction of $437,450.00. Following the completion of the transaction, the director now owns 3,183,756 shares of the company’s stock, valued at approximately $278,546,812.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David T. Howton sold 25,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $105.00, for a total value of $2,625,000.00. Following the sale, the executive vice president now owns 24,388 shares of the company’s stock, valued at approximately $2,560,740. The disclosure for this sale can be found here. Corporate insiders own 6.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC grew its position in shares of Sarepta Therapeutics by 2.7% during the second quarter. Janney Montgomery Scott LLC now owns 4,078 shares of the biotechnology company’s stock worth $620,000 after purchasing an additional 109 shares in the last quarter. ETRADE Capital Management LLC grew its position in shares of Sarepta Therapeutics by 5.2% during the second quarter. ETRADE Capital Management LLC now owns 3,107 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 153 shares in the last quarter. Coastal Investment Advisors Inc. grew its position in shares of Sarepta Therapeutics by 57.4% during the second quarter. Coastal Investment Advisors Inc. now owns 425 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 155 shares in the last quarter. US Bancorp DE grew its position in shares of Sarepta Therapeutics by 16.1% during the second quarter. US Bancorp DE now owns 1,193 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 165 shares in the last quarter. Finally, MML Investors Services LLC grew its position in shares of Sarepta Therapeutics by 8.1% during the second quarter. MML Investors Services LLC now owns 2,230 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 167 shares in the last quarter. Hedge funds and other institutional investors own 97.78% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Further Reading: Bollinger Bands

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Bowling Portfolio Management LLC Has $822,000 Stake in Mastercard Inc
Chemung Financial Corp.  Shares Sold by Bowling Portfolio Management LLC
Chemung Financial Corp. Shares Sold by Bowling Portfolio Management LLC
Cisco Systems, Inc.  Shares Sold by Commerzbank Aktiengesellschaft FI
Cisco Systems, Inc. Shares Sold by Commerzbank Aktiengesellschaft FI
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
Bowling Portfolio Management LLC Has $810,000 Stake in Kennedy-Wilson Holdings Inc
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
State of Alaska Department of Revenue Sells 1,055 Shares of Ferro Co.
Central Garden & Pet Co  Shares Sold by State of Alaska Department of Revenue
Central Garden & Pet Co Shares Sold by State of Alaska Department of Revenue


© 2006-2020 Ticker Report